Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects
The Journal of Infectious Diseases2005Vol. 192(11), pp. 1921–1930
Citations Over TimeTop 1% of 2005 papers
Joel E. Gallant, Allan Rodríguez, Winkler G. Weinberg, Benjamin Young, Daniel S Berger, Michael L. Lim, Qiming Liao, Lisa Ross, Judy Johnson, Mark S. Shaefer, for the ESS30009 Study
Abstract
The tenofovir disoproxil fumarate/abacavir/lamivudine regimen resulted in an unexpected and unacceptably high rate of nonresponse and incidence of K65R and M184V/I. This 3-drug regimen should not be used.
Related Papers
- → Changes in Hematological Parameters After Switching Treatment of HIV-Infected Patients from Zidovudine to Abacavir or Tenofovir DF(2009)4 cited
- A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.(1999)
- → Prognosis of Renal Function, Risk of Dialysis and Mortality in HIV Patients Developing Moderate Impaired Renal Function During Treatment with Tenofovir or Abacavir(2015)
- → Using Abacavir + 3TC + Tenofovir for Treatment Simplification Might Court Virologic Failure(2004)